Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30114819 | 1.00 | PTGER4 (0.81) | PTGER4PTGER2 | |
| SCHEMBL2354632 | 1.00 | PTGER4 (0.81) | PTGER4PTGER2 | |
| SCHEMBL19713682 | 0.94 | PTGER4 (0.80) | PTGER4PTGER2 | |
| SCHEMBL691804 | 0.94 | PTGER4 (0.80) | PTGER4PTGER2 | |
| SCHEMBL5367025 | 0.93 | PTGER4 (0.82) | PTGER4PTGER2 | |
| SCHEMBL1285144 | 0.93 | PTGER4 (0.84) | PTGER4PTGER2 | |
| SCHEMBL19713870 | 0.93 | PTGER4 (0.84) | PTGER4PTGER2 | |
| SCHEMBL5357556 | 0.92 | PTGER4 (0.80) | PTGER4PTGER2 | |
| SCHEMBL19713902 | 0.91 | PTGER4 (0.81) | PTGER4PTGER2 | |
| SCHEMBL2353829 | 0.91 | PTGER4 (0.81) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391086-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | ASKAT INC. (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20180193324-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391086-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | PTGER4, PTGER1, EPB41 | PTGER4 1/4885PTGER2 7/4885 |
| US-20180193324-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, EPB41 | PTGER4 1/4885PTGER2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.